What question did this study set out to answer?

To assess PSMA-617 sensitivity in prostate cancer PDX models and explore combination therapies to overcome resistance.

Mapping PSMA-617 Sensitivity in Prostate Cancer Models for Treatment Strategies

View Full Paper

Ask AI

Bookmark

To assess PSMA-617 sensitivity in prostate cancer PDX models and explore combination therapies to overcome resistance.
Utilized prostate cancer PDX models selected based on PSMA expression.
Monitored tumor growth after treatment with [177Lu]Lu-PSMA-617 and evaluated therapeutic efficacy using TGI and TTP metrics.
Derived a PSMA-617-resistant PDX model from an initially sensitive tumor to study resistance patterns.
Evaluated the role of PARP inhibition with olaparib as a radiosensitizer in resistant models.
Treatment with [177Lu]Lu-PSMA-617 demonstrated varied responses in PDX models.
Olaparib combination therapy extended tumor relapse duration from 29 to 49 days.
Established PDX models provided robust predictive insights for clinical outcomes.

No takes yet. Share an insight, caveat, or question.

Preclinical models evaluate PSMA-617 sensitivity in prostate cancer, suggesting effective combination therapies for resistance.

Sanchez et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark